Advertisement: TTP Killer 50
18 April, 2019 - 23:45 By Jamie Quested aims to give life science researchers access to cheaper antibodies for use in areas such as cancer, neuroscience and epigenetics and is closing in on its first round of funding.

Shocked at the high prices being charged by vendors, father-and-son co-founders Stewart and Sebastian Newlove decided to start sourcing a wide range of identical antibodies from the same manufacturers and provide them to researchers at far more competitive prices. offers a range of more than 70,000 products and is already making sales globally. So far, the company has been focused on establishing agreements with antibody manufacturers and the development of their online marketplace. 

According to a study by Grand View Research, the antibody production market will be worth $22.6 billion by 2025. The Cambridge-headquartered company plans to complete the seed round in Q1 2019.

Newsletter Subscription

Stay informed of the latest news and features